To investigate whether catalpol protects against diabetic retinal vascular endothelial injury by targeting the methyltransferase-like 3 (METTL3)-m⁶A-thioredoxin-interacting protein (TXNIP) axis and inhibiting nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation.

A streptozotocin-induced diabetic mouse model (n=20 per group) was used to assess retinal function via electroretinogram (ERG) and vascular integrity via Evans Blue leakage. Human retinal vascular endothelial cells (HRVECs) were exposed to high glucose (HG, 30 mmol/L) with or without catalpol or the METTL3 inhibitor STM2457. NLRP3 inflammasome components (Western blot), oxidative stress (DCFH-DA probe), global m⁶A levels (Dot blot), and TXNIP expression were measured. The binding of catalpol to METTL3, NLRP3, TXNIP, and interleukin-1β (IL-1β) was analyzed via molecular docking and dynamics simulations.

Catalpol treatment improved ERG amplitudes [a-wave, b-wave, oscillatory potentials (OPs)] and reduced vascular leakage in diabetic mice (P<0.05), while downregulating retinal vascular endothelial growth factor (VEGF), NLRP3, IL-1β, and IL-18 protein levels. In HG-stimulated HRVECs, catalpol inhibited the NLRP3-apoptosis-associated speck-like protein containing a CARD (ASC)-caspase-1 inflammasome, reduced reactive oxygen species, and suppressed METTL3 expression and global m⁶A methylation (P<0.05). It also attenuated HG-induced TXNIP upregulation. METTL3 inhibition by STM2457 mimicked all protective effects of catalpol. Molecular simulations confirmed stable binding of catalpol to METTL3, NLRP3, TXNIP, and IL-1β.

Catalpol alleviates diabetic retinal vascular endothelial injury by inhibiting the NLRP3 inflammasome. This effect is mediated, at least in part, through downregulating METTL3-dependent m⁶A RNA methylation of TXNIP.

To compare the short-term effectiveness of intelligent navigated laser photocoagulation and 577-nm subthreshold micropulse laser (SML) treatment in patients with chronic central serous chorioretinopathy (cCSC).

This observational retrospective cohort study included 60 consecutive patients who underwent intelligent navigated laser photocoagulation (n=30) or 577-nm SML treatment (n=30) for cCSC between Jan. 2021 and Oct. 2022. During 3mo follow-up, all patients underwent assessments of best correct visual acuity (BCVA) and optical coherence tomography (OCT).

The operation of laser treatment was successful in all cases. At 1mo, BCVA improved significantly more in the intelligent navigated laser photocoagulation group compared to the SML group (P<0.05). The change was not significantly different at 3mo (P>0.05). Central macular thickness (CMT) in the intelligent navigated laser photocoagulation group was lower than in the SML group at 1mo (P<0.05). The subfoveal choroidal thickness (SFCT) in two groups were all significantly improved at 3mo (all P<0.05). The change between two groups was not significantly different at 1mo or at 3mo (P>0.05).

Intelligent navigated laser photocoagulation is superior to SML for treating cCSC, leading to better improvements in vision and CMT for short term.